VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200 Day Moving Average of $0.62

VBI Vaccines Inc. (NASDAQ:VBIV)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.62 and traded as low as $0.61. VBI Vaccines shares last traded at $0.66, with a volume of 601,236 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of VBI Vaccines in a research note on Saturday. They issued a “sell” rating for the company.

VBI Vaccines Trading Up 1.5 %

The stock has a fifty day moving average of $0.61 and a 200-day moving average of $0.62.

VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. The business had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.85 million. On average, analysts anticipate that VBI Vaccines Inc. will post -1.23 EPS for the current year.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.